Keros Therapeutics (KROS) Current Leases (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Current Leases came in at $2.4 million in Q4 2025, up 21.74% YoY from $2.0 million in Q4 2024, and up 3.88% on a QoQ basis from $2.3 million in Q3 2025.
Keros Therapeutics (KROS) Current Leases (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Current Leases data on file, last reported at $2.4 million in Q4 2025.
- Quarterly Current Leases rose 21.74% year-over-year to $2.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (up 21.74% YoY) and the FY2025 annual result came in at $2.4 million, up 21.74% from the prior year.
- Current Leases rose to $2.4 million in Q4 2025, from $2.3 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $2.4 million in Q4 2025 to a low of $436000.0 in Q1 2021.
- A 5-year average of $1.2 million and a median of $944500.0 in 2022 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases plunged 47.22% — and 2024, when it soared 203.93%.
- Tracing KROS's Current Leases over 5 years: stood at $862000.0 in 2021, then sank by 47.22% to $455000.0 in 2022, then jumped by 120.88% to $1.0 million in 2023, then soared by 96.82% to $2.0 million in 2024, then gained by 21.74% to $2.4 million in 2025.
- The last three Current Leases figures came in at $2.4 million (Q4 2025), $2.3 million (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Keros Therapeutics | 217.21 Mn | -40.40 Mn | - | 2.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.60 Mn |
| Dec 31, 2025 | 2.41 Mn |
| Sep 30, 2025 | 2.32 Mn |
| Jun 30, 2025 | 2.23 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Sep 30, 2024 | 1.86 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.05 Mn |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 611,000.00 |
| Dec 31, 2022 | 455,000.00 |
| Sep 30, 2022 | 455,000.00 |
| Jun 30, 2022 | 670,000.00 |
| Mar 31, 2022 | 884,000.00 |
| Dec 31, 2021 | 862,000.00 |
| Sep 30, 2021 | 843,000.00 |
| Jun 30, 2021 | 449,000.00 |
| Mar 31, 2021 | 436,000.00 |
| Dec 31, 2020 | 423,000.00 |